New Zealand · Delayed Price · Currency is NZD Pacific Edge Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and test volumes declined sharply due to Medicare non-coverage, resulting in a $19.1M net loss and increased reliance on cash reserves. Strategic milestones include a price increase for Triage Plus and a key policy review by Novitas in early 2026, with recovery dependent on appeal outcomes.
Fiscal Year 2025
-
The meeting highlighted strategic progress with AUA guideline inclusion and a successful capital raise, despite the significant challenge of losing Medicare coverage. The board emphasized governance, risk management, and a pivot to commercial payers, with all resolutions passed by strong shareholder support.
-
Test volumes and revenue declined year-over-year, but commercial payer mix and sales efficiency improved. Major clinical guideline inclusion and a capital raise position the business for future growth, with Medicare coverage reinstatement a key catalyst.
-
Operating revenue rose 1.4% half-on-half but fell 16.3% year-over-year, with net loss steady at NZD 14.5 million and cash reserves at NZD 35.9 million. Strategic focus is on Triage Plus launch, Medicare coverage, and expanding APAC presence.
Fiscal Year 2024
-
The meeting reviewed strong revenue growth and operational resilience despite Medicare uncertainty, highlighted strategic focus on U.S. and Asia-Pacific markets, and discussed new product launches and digital initiatives. Shareholders supported all resolutions, and leadership addressed key risks and future plans.